MET and non-small cell lung carcinoma: MET mutations can be detected in 3% to 5% of patients with non-small cell lung cancer (mainly adenocarcinoma) and occur more frequently in PSC, and METex14 skipping mutation is the most common and well-studied mutation type, occurring in about 3%-4% of adenocarcinoma patients and 22% of PSC patients (15, 16).